Evolus, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 21, 2021, reports on Evolus, Inc.'s entry into a material definitive agreement for an underwritten public offering of common stock. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newport Beach, California.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 9,000,000 shares of Common Stock (Firm Shares) at a public offering price of $9.50 per share.
- Purchase Price: Underwriters purchased shares at $8.93 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,350,000 additional shares at the purchase price.
- Net Proceeds: Estimated at approximately $80.1 million from the Firm Shares, potentially increasing to $92.1 million if the option is fully exercised.
- Cash Position (Preliminary): As of March 31, 2021, the Company estimated cash and cash equivalents at approximately $22.2 million. On a pro forma basis, including a $25.5 million settlement payment received from Daewoong Pharmaceuticals Co., Ltd. on April 6, 2021, cash was estimated at $47.7 million.
- Use of Proceeds: Funding U.S. growth of Jeuveau, European pre-launch activities, and general corporate purposes.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement on April 21, 2021, and the completion of the Offering on April 26, 2021. Additionally, the Company and certain officers, directors, and stockholders entered into "lock-up" agreements prohibiting the sale or transfer of securities for 60 days from April 21, 2021.
Outlook, Risks, and Unusual Items
The filing notes that the preliminary cash estimates as of March 31, 2021, have not been reviewed by the independent registered public accounting firm and are subject to change upon completion of financial statement closing procedures. The Company advises that undue reliance should not be placed on these preliminary estimates. The filing references the "Risk Factors" section of the 2020 Annual Report for a comprehensive view of risks.
Investor Verification Checklist
- Verify the final net proceeds after deducting all underwriting discounts, commissions, and offering expenses.
- Confirm whether the underwriters exercised the 1,350,000 share over-allotment option within the 30-day window.
- Review the audited financial statements in the 2020 Annual Report (Form 10-K) to reconcile the preliminary cash estimates provided in this 8-K.
- Monitor the Company's progress on the stated use of proceeds, specifically the U.S. growth of Jeuveau and European pre-launch activities.